(Q33431538)

26 July 2017

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial (English)

1 reference

26 July 2017

phase III clinical trial

0 references

1 reference

1 reference

3

Agnès Guerci-Bresler

1 reference

26 July 2017

François Guilhot

20

0 references

Andreas Hochhaus

object named as

Andreas Hochhaus

21

0 references

Hagop Kantarjian

23

object named as

Hagop M Kantarjian

1 reference

26 July 2017

4

Gianantonio Rosti

1 reference

26 July 2017

18

Michele Baccarani

1 reference

26 July 2017

19

Jorge E Cortes

1 reference

26 July 2017

9

Philipp le Coutre

1 reference

26 July 2017

2

Charles Chuah

1 reference

26 July 2017

11

Leif Stenke

1 reference

26 July 2017

13

Vivian Oehler

1 reference

26 July 2017

25

Moshe Talpaz

1 reference

26 July 2017

6

Sarit Assouline

1 reference

26 July 2017

14

Stephanie Lustgarten

1 reference

26 July 2017

17

Frank G Haluska

1 reference

26 July 2017

Jeffrey H Lipton

1

1 reference

26 July 2017

David Simpson

5

1 reference

26 July 2017

Gabriel Etienne

7

1 reference

26 July 2017

Franck E Nicolini

8

1 reference

26 July 2017

Richard E Clark

10

1 reference

26 July 2017

David Andorsky

12

1 reference

26 July 2017

Victor M Rivera

15

1 reference

26 July 2017

Timothy Clackson

16

1 reference

26 July 2017

Timothy Hughes

22

1 reference

26 July 2017

Neil P Shah

24

1 reference

26 July 2017

Michael W Deininger

26

1 reference

26 July 2017

EPIC investigators

27

1 reference

26 July 2017

12 April 2016

1 reference

Lancet Oncology Commission

26 July 2017

1 reference

26 July 2017

17

1 reference

26 July 2017

5

1 reference

26 July 2017

612-621

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Abl family kinases regulate endothelial barrier function in vitro and in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2900080-2

7 January 2021

10.1016/S1470-2045(16)00080-2

Identifiers

DOI

1 reference

26 July 2017

1 reference